{"role": "user", "content": "Label: breast carcinoma metastasis in sentinel lymph node.\nGoal: propose search plan, then call search_pubmed for key phrases.", "tool_calls": null, "name": null, "tool_call_id": null}
{"role": "assistant", "content": "To effectively search for literature related to \"breast carcinoma metastasis in sentinel lymph node,\" we can break down the search into key phrases and relevant keywords. Here’s a proposed search plan:\n\n### Search Plan\n\n1. **Key Phrases and Keywords**:\n   - \"breast carcinoma\"\n   - \"breast cancer\"\n   - \"metastasis\"\n   - \"sentinel lymph node\"\n   - \"lymphatic spread\"\n   - \"tumor staging\"\n   - \"diagnosis\"\n   - \"prognosis\"\n   - \"treatment\"\n   - \"pathology\"\n\n2. **Search Strategy**:\n   - Combine the key phrases using Boolean operators (AND, OR).\n   - Example search queries:\n     - \"breast carcinoma AND sentinel lymph node AND metastasis\"\n     - \"breast cancer AND lymphatic spread\"\n     - \"sentinel lymph node AND tumor staging AND prognosis\"\n\n3. **Focus Areas**:\n   - Mechanisms of metastasis in breast cancer.\n   - Diagnostic techniques for detecting metastasis in sentinel lymph nodes.\n   - Prognostic implications of sentinel lymph node involvement in breast carcinoma.\n\n### Execution\nNow, I will perform a search on PubMed using the key phrases identified in the search plan. I will start with the first query: \"breast carcinoma AND sentinel lymph node AND metastasis\". \n\nLet's proceed with the search.", "tool_calls": [{"name": "search_pubmed", "args": {"query": "breast carcinoma AND sentinel lymph node AND metastasis"}, "id": "call_ZXgA6prv1ADT3PMBrX1Cm7oj", "type": "tool_call"}], "name": null, "tool_call_id": null}
{"role": "tool", "content": "[{\"title\": \"Factors Predicting Additional Residual Nodal Disease With a Metastatic Sentinel Node Biopsy or Targeted Axillary Dissection After Neoadjuvant Chemotherapy.\", \"snippet\": \"This study aimed to investigate whether specific clinicopathological characteristics are associated with a lower likelihood of additional positive nodes (APNs) on completion axillary lymph node dissection (cALND). A total of 497 patients with cT1-4/N1-3 disease underwent cALND following a positive sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NAC). The APN rate was assessed based on findings from the cALND. The median age was 47 (21-84). The overall APN rate was 67.6%. Patients with cT1-2 disease, a breast pathological complete response, removal of > two nodes via SLNB or TAD, only one metastatic node identified at SLNB or TAD, a lymph node ratio (LNR) < 50%, or low-volume metastatic disease (including isolated tumor cells [ITCs] or\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/41022401/\"}, {\"title\": \"Breast mucoepidermoid carcinoma: A case report.\", \"snippet\": \"The present study reports the case of a 43-year-old female patient who underwent surgical excision of a right breast mass. Gross examination revealed a cystic lesion. Histopathological examination demonstrated a solid cystic tumor with intraluminal papillary projections. The neoplasm was composed of mildly atypical intermediate, epidermoid, mucinous and eosinophilic cells, exhibiting cribriform glandular patterns, and microcystic structures containing mucinous or eosinophilic secretions. Peritumoral lymphoid hyperplasia was observed in adjacent mammary gland tissue. Immunohistochemical results showed that p63, cytokeratin (CK) 5/6 and CK7 exhibited zonal positive staining; GATA binding protein 3 was positive; S-100 and SYN were negative; the estrogen receptor positive rate was 20%; progest\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/41018155/\"}, {\"title\": \"Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes.\", \"snippet\": \"In the era of therapeutic de-escalation, the opportunity to move from systematic axillary lymph node dissection (ALND) to sentinel lymph node biopsy in axillary node-positive breast cancer patients after neoadjuvant systemic therapy (NST) is currently considered. The purpose of this study was to identify FDG-PET parameters associated with axillary pathological complete response (pRAx) in the most proliferative tumor subtypes, eg Triple Negative (TN) and HER2-amplified. Patients with newly-diagnosed TN or HER2-amplified breast cancer, with pathologically-proven axillary node metastasis, no distant metastasis and indication of NST were prospectively included from September 2017 to December 2021. Sequential FDG-PET/CT scans were performed at baseline and after one cycle of NST. Metabolic para\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/40993786/\"}, {\"title\": \"De-escalating axillary surgery in node-positive early breast cancer patients undergoing primary surgery: current evidence and recommendations.\", \"snippet\": \"Landmark trials have shown that axillary lymph node dissection (ALND) can be safely omitted in early breast cancer patients with 1-2 positive nodes. Despite lack of prospective data, the National Comprehensive Cancer Network (NCCN) guidelines recommend that patients with 1-2 suspicious or biopsy-proven positive lymph nodes having primary surgery can undergo sentinel lymph node biopsy (SLNB). In the era of de-escalation of axillary surgery, breast cancer management in patients with clinically node-positive (cN +) axilla is driven by tumour biology and response to neoadjuvant chemotherapy (NACT). In this review, we discuss the management of the axilla in early breast cancer patients with low-volume biopsy-proven nodal disease and summarise the evidence supporting omission of ALND in these pa\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/40976831/\"}, {\"title\": \"Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study.\", \"snippet\": \"Completion axillary lymph node dissection (cALND) is often recommended for patients with isolated tumour cells (ITCs) or micrometastases in the sentinel lymph node (SLN) or target lymph node (TLN) to assess the definite nodal tumour burden after neoadjuvant chemotherapy (NACT). The aim of this study was to investigate the upgrade of N stage by cALND in patients with low-volume metastases in the SLN/TLN after NACT from the prospective, international, multicentre AXSANA cohort study. NACT-treated patients that converted from a positive to a negative clinical lymph node status and underwent cALND based on low-volume SLN/TLN involvement were included. The association between the final N stage, the pathological tumour response in the breast, and the clinical impact of cALND on post-NACT treatme\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/40966675/\"}]", "tool_calls": null, "name": "search_pubmed", "tool_call_id": "call_ZXgA6prv1ADT3PMBrX1Cm7oj"}
{"role": "assistant", "content": "Here are the results from the PubMed search for \"breast carcinoma AND sentinel lymph node AND metastasis\":\n\n1. **Factors Predicting Additional Residual Nodal Disease With a Metastatic Sentinel Node Biopsy or Targeted Axillary Dissection After Neoadjuvant Chemotherapy.**\n   - **Snippet**: This study aimed to investigate whether specific clinicopathological characteristics are associated with a lower likelihood of additional positive nodes (APNs) on completion axillary lymph node dissection (cALND) following a positive sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NAC).\n   - [Read more](https://pubmed.ncbi.nlm.nih.gov/41022401/)\n\n2. **Breast mucoepidermoid carcinoma: A case report.**\n   - **Snippet**: The present study reports the case of a 43-year-old female patient who underwent surgical excision of a right breast mass. Histopathological examination demonstrated a solid cystic tumor with intraluminal papillary projections.\n   - [Read more](https://pubmed.ncbi.nlm.nih.gov/41018155/)\n\n3. **Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes.**\n   - **Snippet**: The purpose of this study was to identify FDG-PET parameters associated with axillary pathological complete response (pRAx) in the most proliferative tumor subtypes, eg Triple Negative (TN) and HER2-amplified.\n   - [Read more](https://pubmed.ncbi.nlm.nih.gov/40993786/)\n\n4. **De-escalating axillary surgery in node-positive early breast cancer patients undergoing primary surgery: current evidence and recommendations.**\n   - **Snippet**: Landmark trials have shown that axillary lymph node dissection (ALND) can be safely omitted in early breast cancer patients with 1-2 positive nodes. This review discusses the management of the axilla in early breast cancer patients with low-volume biopsy-proven nodal disease.\n   - [Read more](https://pubmed.ncbi.nlm.nih.gov/40976831/)\n\n5. **Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study.**\n   - **Snippet**: The aim of this study was to investigate the upgrade of N stage by completion axillary lymph node dissection (cALND) in patients with low-volume metastases in the sentinel lymph node after neoadjuvant chemotherapy.\n   - [Read more](https://pubmed.ncbi.nlm.nih.gov/40966675/)\n\nThese articles provide insights into various aspects of breast carcinoma metastasis in sentinel lymph nodes, including predictive factors, treatment strategies, and the implications of neoadjuvant therapy. If you would like to explore further or search with different keywords, please let me know!", "tool_calls": [], "name": null, "tool_call_id": null}
